Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. Mai 2013 09:00 ET | Quelle: Lpath, Inc.

Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP

SAN DIEGO, May 30, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark...
23. Mai 2013 09:00 ET | Quelle: Lpath, Inc.

Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP

SAN DIEGO, May 23, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics,has initiated dosing in a Phase 2a single-arm trial where...
16. April 2013 16:15 ET | Quelle: Lpath, Inc.

Lpath Adds Two Key Members to its Executive Team

SAN DIEGO, April 16, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics, has added two key members to its leadership team. Dario A....